Adaptimmune Therapeutics plc (473A) — Financial Flexibility Index
Adaptimmune Therapeutics plc (473A) has a Financial Flexibility Index of -0.17x as of June 2025. Free cash flow of €-34.70 Million (operating CF €-34.78 Million minus capex €75.00K) represents 0% of total liabilities (€201.59 Million). Check Adaptimmune Therapeutics plc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Adaptimmune Therapeutics plc Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for Adaptimmune Therapeutics plc across 9 annual periods. For the full cash flow conversion analysis, see Adaptimmune Therapeutics plc cash flow conversion.
Annual Financial Flexibility Index for Adaptimmune Therapeutics plc (2016–2024)
Year-by-year free cash flow to debt coverage for Adaptimmune Therapeutics plc. Explore 473A cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -0.30x | €-70.49 Million | €-73.21 Million | €234.11 Million | ▲ +46.2% |
| 2023 | -0.56x | €-136.00 Million | €-140.88 Million | €243.10 Million | ▼ -23.1% |
| 2022 | -0.45x | €-112.27 Million | €-141.77 Million | €247.04 Million | ▼ -720.6% |
| 2021 | 0.07x | €19.30 Million | €10.73 Million | €263.58 Million | ▲ +115.7% |
| 2020 | -0.47x | €-51.25 Million | €-53.59 Million | €109.92 Million | ▲ +75.7% |
| 2019 | -1.92x | €-110.92 Million | €-112.51 Million | €57.91 Million | ▲ +43.1% |
| 2018 | -3.37x | €-100.48 Million | €-104.39 Million | €29.85 Million | ▼ -786.7% |
| 2017 | -0.38x | €-29.67 Million | €-54.31 Million | €78.16 Million | ▲ +26.6% |
| 2016 | -0.52x | €-35.38 Million | €-48.17 Million | €68.37 Million | — |